MedTrace Logo

Cytokines and Chemokines in Erythema Migrans

NCT02147249 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2019-04-22

No results posted yet for this study

Summary

The main objective of this study is to characterize the inflammatory proteins, gene polymorphisms, and transcriptome profiles in patients with erythema migrans to gain better insight into pathogenesis of early Lyme borreliosis and to define new immune modulators that could serve as biomarkers of disease activity.

Conditions

  • Erythema Migrans

Interventions

DRUG

antibiotic treatment

Patient will be treated with: doxycycline orally, 100 mg, bid, 14 days or cefuroxime axetil orally, 500 mg, bid, 14 days or amoxicillin orally, 500 mg, tid, 14 days

Sponsors & Collaborators

  • University of Ljubljana School of Medicine, Slovenia

    collaborator OTHER

  • Medical University of Vienna

    collaborator OTHER

  • Harvard University

    collaborator OTHER

  • University Medical Centre Ljubljana

    lead OTHER

Principal Investigators

  • Franc Strle, MD, PhD · UMC Ljubljana

  • Dasa Stupica, MD, PhD · UMC Ljubljana

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Slovenia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02147249 on ClinicalTrials.gov